Search Results - "ŁOpaciuk, S."

Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene by HERRMANN, F. H., AUERSWALD, G., RUIZ-SAEZ, A., NAVARRETE, M., POLLMANN, H., LOPACIUK, S., BATOROVA, A., WULFF, K.

“…Inherited factor X deficiency (FXD) is a rare (1:1 000 000) recessive bleeding disorder. The clinical and laboratory phenotypes of FXD are poorly correlated…”
Get full text

Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis by Lopaciuk, S, Bielska-Falda, H, Noszczyk, W, Bielawiec, M, Witkiewicz, W, Filipecki, S, Michalak, J, Ciesielski, L, Mackiewicz, Z, Czestochowska, E, Zawilska, K, Cencora, A

“…The aim of this study was to determine the efficacy and safety of subcutaneous weight-adjusted dose low molecular weight heparin (LMWH) compared with oral…”
Get more information

Degradation of glycophorin A of human erythrocytes in patients with myelo‐ or lymphoproliferative disorders: possible role of neutrophil proteases by Bykowska, K., Duk, M., Kuśnierz‐Alejska, G., Sikorska, A., ŁE¸towska, M., Mendek‐Czajkowska, E., ŁOpaciuk, S., Kopeć, M., Lisowska, E.

“…We have previously reported that glycophorin A (GPA) of human erythrocytes (carrying blood group M and N determinants) was totally digested by incubation of…”
Get full text

An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies by MAUSER-BUNSCHOTEN, E. P., KLEINE BUDDE, I., LOPACIUK, S., KOOPMAN, M. M. W., Van Der MEER, F. J. M., NOVÀKOVÀ, I. R. O., YPMA, P., Van Der LINDEN, P. W. G., WINDYGA, J., STRENGERS, P. F. W.

“…Nonafact®, an ultrapure, monoclonal antibody‐purified factor IX concentrate (FIX) was developed to minimize risk of thrombotic complications and viral…”
Get full text

Haemophilia in Poland by WINDYGA, J., LOPACIUK, S., STEFANSKA, E., JUSZYNSKI, A., WOZNIAK, D., STRZELECKI, O., SZCZEPANIK, A. B.

“…The primary aim of this study was to analyse the data on 2269 haemophilic patients in the Polish National Register of Inherited Bleeding Disorders – 1953…”
Get full text

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement by Rodriguez-Merchan, E. C., Rocino, A., Ewenstein, B., Bartha, L., Batorova, A., Goudemand, J., Gringeri, A., Joao-Diniz, M., Lopaciuk, S., Negrier, C., Quintana, M., Tagariello, G., Tjonnfjord, G. E., Villar, V A., Vorlova, Z.

“…Participants in an international workshop on surgery in haemophilia patients with inhibitors developed a consensus summary of the findings and conclusions of…”
Get full text

Alterations of blood platelet function induced by neutral proteases from human leukocytes by Bykowska, K, Kaczanowska, J, Karpowicz, M, Lopaciuk, S, Kopeć, M

“…Washed human platelets are damaged by two neutral proteases from human leukocytes (elastase-like protease, ELP and chymotrypsin-like protease, CLP). The damage…”
Get more information

Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke by Lopaciuk, S, Bykowska, K, Kwiecinski, H, Mickielewicz, A, Czlonkowska, A, Mendel, T, Kuczynska-Zardzewialy, A, Szelagowska, D, Windyga, J, Schröder, W, Herrmann, F H, Jedrzejowska, H

“…Ischemic stroke in young adults is a well-known disease, but despite extensive clinical and laboratory investigations, its etiology remains unclear in…”
Get more information

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A by Wolf, D. M., Rokicka-Milewska, R., Lopaciuk, S., Skotnicki, A. B., Klukowska, A., Laguna, P., Windyga, J., Kotitschke, R., Struff, W. G.

“…Clinical efficacy, safety and pharmacokinetic properties of the high‐purity double‐virus inactivated plasma‐derived factor VIII concentrate Haemoctin® SDH…”
Get full text

Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial by Lopaciuk, S, Meissner, A J, Filipecki, S, Zawilska, K, Sowier, J, Ciesielski, L, Bielawiec, M, Glowinski, S, Czestochowska, E

“…In a prospective multicenter trial, 149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg were randomly…”
Get more information

Prevalence of factor V Leiden mutation in various populations by Herrmann, F.H., Koesling, M., Schröder, W., Altman, R., Bonilla, R. Jiménez, Lopaciuk, S., Perez-Requejo, J.L., Singh, J.R.

“…Resistance to activated protein C (APC) is the most common inherited risk factor for venous thrombosis. Most cases of APC resistance are caused by the point…”
Get full text

Bovine platelet proteins. II. Purification of platelet fibrinogen by Solum, N O, Lopaciuk, S

Get more information

Inherited thrombophilia and complications of pregnancy by Łopaciuk, S

Get more information

Inherited thrombophilia: pathogenesis, clinical and treatment aspects by Łopaciuk, S

Get more information

Monocytes of patients congenitally deficient in plasma factor XIII lack factor XIII subunit a antigen and transglutaminase activity by Muszbek, L, Adány, R, Kávai, M, Boda, Z, Lopaciuk, S

“…Monocytes isolated from patients with severe deficiency in plasma Factor XIII of blood coagulation (FXIII) were tested for FXIII antigen and transglutaminase…”
Get more information

Venostasis but not DDAVP infusion provokes the plasma fibronectin increase by Letowska, M, Bykowska, K, Sablinski, J, Lopaciuk, S, Kopeć, M

“…Plasma fibronectin (pFN), von Willebrand factor antigen (vWf:Ag), factor VIII procoagulant activity, fibrinogen, euglobulin lysis time (ELT) and hematocrit…”
Get more information

Different effects of human neutrophil elastase on platelet glycoproteins IIb and IIIa of resting and stimulated platelets by Bykowska, K, Pawlowska, Z, Cierniewski, C, Lopaciuk, S, Kopeć, M

“…The effect of human neutrophil elastase (HNE) on the structure and receptor activity of platelet glycoprotein IIb/IIIa complex was studied. Resting platelets,…”
Get more information

Prevalence of G20210A prothrombin gene mutation in Poland by Bykowska, K, Vertun-Baranowska, B, Windyga, J, Łopaciuk, S

“…The G20210A mutation of the prothrombin (PT) gene has recently been identified as a risk factor for venous thromboembolism (VTE). This mutation was shown to be…”
Get more information

Effects of human neutrophil elastase and cathepsin G on the reactivity of platelets with antiplatelet antibodies by Bykowska, K, Maślanka, K, Uhrynowska, M, Kopeć, M, Lopaciuk, S

“…Two human neutrophil serine proteases, elastase (HNE) and cathepsin G (CathG), are known to change the structure and hemostatic function of platelet surface…”
Get more information

Subcellular distribution of fibrinogen and factor XIII in human blood platelets by Lopaciuk, S, Lovette, K M, McDonagh, J, Chuang, H Y, McDonagh

Get more information